2
Injectable drugs
There are several new and promising therapies available to
treat post-op inflammation in the eye and ocular pain following
cataract surgery:
• Dexycu (dexamethasone intraocular suspension) from EyePoint
Pharmaceuticals is a well-trusted and potent single-dose, sustained-
release steroid, says John Hovanesian, MD, of Harvard Eye
Associates in Laguna Hills, Calif. Surgeons administer a 5-micron
dose into the ciliary sulcus at the end of surgery, after they've
implanted the IOL and removed the viscoelastic, he says. After
injection, Dexycu transitions into a white liquid sphere in the ante-
rior chamber and slowly dissolves to deliver a steady-state dose of
the steroid inside the eye for a month.
"It's FDA approved and has an acceptable safety profile, meaning it
doesn't increase risk of intraocular pressure spikes more than topical
dexamethasone," says Dr. Hovanesian.
Last month, CMS assigned a J-code for Dexycu, J1095, which takes
effect Jan. 1, and will replace the previously issued C-code for Dexycu
